Markus Krauss
Markus Krauss
M&S Scientist, DMPK Project Manager, Bayer AG
Bestätigte E-Mail-Adresse bei bayer.com
Titel
Zitiert von
Zitiert von
Jahr
Integrating cellular metabolism into a multiscale whole-body model
M Krauss, S Schaller, S Borchers, R Findeisen, J Lippert, L Kuepfer
PLoS Comput Biol 8 (10), e1002750, 2012
1112012
A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation
C Thiel, S Schneckener, M Krauss, A Ghallab, U Hofmann, T Kanacher, ...
Journal of pharmaceutical sciences 104 (1), 191-206, 2015
832015
Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals
JF Schlender, M Meyer, K Thelen, M Krauss, S Willmann, T Eissing, ...
Clinical pharmacokinetics 55 (12), 1573-1589, 2016
552016
Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification
M Krauss, R Burghaus, J Lippert, M Niemi, P Neuvonen, A Schuppert, ...
In silico pharmacology 1 (1), 6, 2013
462013
Spatio-temporal simulation of first pass drug perfusion in the liver
LO Schwen, M Krauss, C Niederalt, F Gremse, F Kiessling, A Schenk, ...
PLoS Comput Biol 10 (3), e1003499, 2014
442014
Bayesian population physiologically-based pharmacokinetic (PBPK) approach for a physiologically realistic characterization of interindividual variability in clinically relevant …
M Krauss, K Tappe, A Schuppert, L Kuepfer, L Goerlitz
PloS one 10 (10), e0139423, 2015
362015
Translational learning from clinical studies predicts drug pharmacokinetics across patient populations
M Krauss, U Hofmann, C Schafmayer, S Igel, J Schlender, C Mueller, ...
NPJ systems biology and applications 3 (1), 1-11, 2017
82017
A multiscale, model-based analysis of the multi-tissue interplay underlying blood glucose regulation in type I diabetes
F Wadehn, S Schaller, T Eissing, M Krauss, L Küpfer
2016 38th Annual International Conference of the IEEE Engineering in …, 2016
52016
Assessing interindividual variability by Bayesian-PBPK modeling
M Krauss, A Schuppert
Drug Discovery Today: Disease Models 22, 15-19, 2016
32016
A Systems Pharmacology Approach for Translational Learning and Pharmakokinetic Predictions across Patient Populations
M Krauss, C Mueller, J Schlender, A Schuppert, M Block, L Kuepfer
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 43, S67-S68, 2016
2016
Predicting morphine drug exposure in elderly using an age-informed physiologically based pharmacokinetic approach
JF Schlender, M Meyer, K Thelen, M Krauss, M Block, S Willmann, ...
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 43, S100-S100, 2016
2016
Bayesian population PBPK approach for support of drug development
M Krauß, A Schuppert, A Mitsos
Lehrstuhl für Datengetriebene Modellierung in der Computational Engineering …, 2016
2016
Virtueller Blutfluss: die Leber in silico
LO Schwen, M Krauss, C Niederalt
Journal Club AINS 3 (02), 107-107, 2014
2014
Bayesian Population PBPK Approach for Support of Drug Development Bayesscher Populations-PBPK Ansatz zur Unterstützung der Medikamentenentwicklung
M Krauß
Population Approach Group Europe Population Approach Group Europe
P Denti
A SPATIO-TEMPORALLY RESOLVED HEPATIC PHARMACOKINETICS MODEL
LO Schwen¹, M Krauss, F Gremse, F Kiessling, T Preusser¹, L Küpfer
Please select your preffered valuta to pay
M Krauß
Population Approach Group Europe Population Approach Group Europe
C Diedrich
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–18